[{"address1": "3400 One First Canadian Place", "city": "Toronto", "state": "ON", "zip": "M5X 1A4", "country": "Canada", "website": "https://www.vaxil-bio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment. The company was founded in 2006 and is headquartered in Toronto, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. David  Goren", "title": "CEO & Chairman", "fiscalYear": 2021, "totalPay": 76133, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gadi  Levin B.Com., C.A., CPA, M.B.A.", "age": 50, "title": "CFO & Director", "yearBorn": 1973, "fiscalYear": 2021, "totalPay": 72437, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riva  Kovjazin M.D.", "title": "Senior Scientist & Member of Scientific Advisory Board", "fiscalYear": 2021, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.02, "open": 0.0149, "dayLow": 0.0149, "dayHigh": 0.0149, "regularMarketPreviousClose": 0.02, "regularMarketOpen": 0.0149, "regularMarketDayLow": 0.0149, "regularMarketDayHigh": 0.0149, "beta": -3.527, "volume": 1000, "regularMarketVolume": 1000, "averageVolume": 11714, "averageVolume10days": 8210, "averageDailyVolume10Day": 8210, "marketCap": 2040987, "fiftyTwoWeekLow": 0.0021, "fiftyTwoWeekHigh": 0.06, "fiftyDayAverage": 0.017978, "twoHundredDayAverage": 0.013315, "currency": "USD", "enterpriseValue": 1031986, "floatShares": 125693275, "sharesOutstanding": 136979008, "heldPercentInsiders": 0.08164, "heldPercentInstitutions": 0.00018999999, "impliedSharesOutstanding": 137554000, "bookValue": 0.006, "priceToBook": 2.4833333, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -453000, "trailingEps": -0.01, "enterpriseToEbitda": -2.261, "52WeekChange": -0.068750024, "SandP52WeekChange": 0.3288405, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "VXLLF", "underlyingSymbol": "VXLLF", "shortName": "VAXIL BIO LTD (CA)", "longName": "Vaxil Bio Ltd.", "firstTradeDateEpochUtc": 1459344600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9e7b383f-26e7-3815-92b9-aa2ae181b474", "messageBoardId": "finmb_108333814", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.0149, "recommendationKey": "none", "totalCash": 1009000, "totalCashPerShare": 0.007, "ebitda": -456500, "quickRatio": 5.526, "currentRatio": 5.526, "returnOnAssets": -0.20674999, "returnOnEquity": -0.41906, "freeCashflow": -501250, "operatingCashflow": -675000, "financialCurrency": "CAD", "trailingPegRatio": null}]